Generic Name and Formulations:
Sulfacetamide sodium 10%; oph. soln; contains benzalkonium chloride.
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Bacterial Conjunctivitis Drug Treatments
- Soft Tissue Sarcoma Treatment Regimens
- Cervical Cancer Treatment Regimens
Indications for BLEPH-10:
Susceptible infections of conjunctiva and cornea. Adjunct in trachoma.
Adults and Children:
<2months: not recommended. ≥2months: Conjunctivitis: 1–2 drops every 2–3 hrs during the day (less often at night). Trachoma: 2 drops every 2 hrs w. systemic therapy.
Purulent exudates may inactivate drug. Discontinue if hypersensitivity or rash occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Incompatible with silver-containing preparations. May be antagonized by PABA.
Local irritation, stinging, burning, superinfection, sensitization.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib